

1 **Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation**
2 **clocks: a longitudinal study on senolytic interventions**

3 Edwin Lee ^{#1}, Natàlia Carreras-Gallo ^{#2}, Leilani Lopez ², Logan Turner ², Aaron Lin², Tavis L.
4 Mendez ², Hannah Went ², Alan Tomusiak³, Eric Verdin³, Michael Corley⁴, Lishomwa Ndhlovu⁴,
5 Ryan Smith ², Varun B. Dwaraka ^{2*}

6 ¹ Institute For Hormonal Balance, Orlando, FL, United States

7 ² TruDiagnostic, Lexington, KY, United States

8 ³ Buck Institute for Research on Aging, Novato, CA, United States

9 ⁴ Cornell University, Ithaca, NY, United States

10 # These authors contributed equally

11 *Corresponding author: Varun B Dwaraka - varun@trudiagnostic.com

12

13 Keywords

- 14 - Senolytics
- 15 - Longitudinal Study
- 16 - Epigenetic clocks
- 17 - Aging
- 18 - Immune system

19 Abstract

20 Senolytics, small molecules targeting cellular senescence, have emerged as potential
21 therapeutics to enhance health span. However, their impact on epigenetic age remains
22 unstudied. This study aimed to assess the effects of Dasatinib and Quercetin (DQ) senolytic
23 treatment on DNA methylation (DNAm), epigenetic age, and immune cell subsets. In a Phase I
24 pilot study, 19 participants received DQ for 6 months, with DNAm measured at baseline, 3
25 months, and 6 months. Significant increases in epigenetic age acceleration were observed in
26 first-generation epigenetic clocks and mitotic clocks at 3 and 6 months, along with a notable
27 decrease in telomere length. However, no significant differences were observed in second and
28 third-generation clocks. Building upon these findings, a subsequent investigation evaluated the
29 combination of DQ with Fisetin (DQF), a well-known antioxidant and antiaging senolytic
30 molecule. After one year, 19 participants (including 10 from the initial study) received DQF for 6
31 months, with DNAm assessed at baseline and 6 months. Remarkably, the addition of Fisetin to
32 the treatment resulted in non-significant increases in epigenetic age acceleration, suggesting a
33 potential mitigating effect of Fisetin on the impact of DQ on epigenetic aging. Furthermore, our
34 analyses unveiled notable differences in immune cell proportions between the DQ and DQF
35 treatment groups, providing a biological basis for the divergent patterns observed in the
36 evolution of epigenetic clocks. These findings warrant further research to validate and
37 comprehensively understand the implications of these combined interventions.

38 Introduction

39 Senescence is defined as a stable growth arrest of cells that can limit the proliferation of
40 damaged cells, which is important for tissue homeostasis [1], [2]. However, senescent cells also
41 release harmful substances that can cause inflammation and damage to nearby healthy cells
42 [1], [3]. Recent studies suggest that senescence may contribute to aging and age-related
43 pathologies through the impossibility of tissue renewal by the stem cells caught in senescence
44 or through the chronic inflammation of nearby cells that can lead to tissue dysfunction [4]–[6]. In
45 fact, studies in mice have demonstrated that injecting senescent cells can induce age-related
46 conditions like osteoarthritis, frailty, and reduced lifespan [7], [8].

47 Aging is characterized by gradual functional decline [9]. It is associated with increased risk of
48 multiple chronic diseases, geriatric syndromes, impaired physical resilience, and mortality [9]–
49 [11]. For this reason, the pursuit of strategies to combat age-related diseases and promote
50 healthy aging has increased in recent years.

51 Given the potential role of senescence in aging, senolytic drugs have emerged as promising
52 candidates for extending lifespan. Some initially identified senolytics were Dasatinib, Quercetin,
53 and Fisetin [12]. These molecules were drugs or natural products already used for other
54 indications in humans, including anti-cancer therapies [13]–[15]. Dasatinib is a tyrosine kinase
55 inhibitor approved by the FDA to treat myeloid leukemia [12], [16]. Quercetin is a flavonoid
56 compound that induces apoptosis in senescent endothelial cells [12], [16]. Combined treatment
57 with Dasatinib and Quercetin (DQ) has been demonstrated to decrease senescent cell burden
58 in humans in multiple tissues [12], [17]–[20]; improve pulmonary and physical function along
59 with survival in mice while lessening their age-dependent intervertebral disc degeneration [7],
60 [21], [22]; and reduce senescence and inflammatory markers in non-human primates [23]. In
61 human studies, patients with idiopathic pulmonary fibrosis, a senescence associated disease,
62 improved 6-minute walk distance, walking speed, chair rise ability and short physical
63 performance battery after 9 doses of oral DQ over 3 weeks [24]. Fisetin is another flavonoid
64 compound that has gained recognition for its anti-proliferative, anti-inflammatory, and anti-
65 metastatic properties [15], [25]. Fisetin has the potential to reduce senescence markers in
66 multiple tissues in murine and human subjects [12], [26]. Administration of Fisetin to old mice
67 restored tissue homeostasis, reduced age-related pathology, and extended median and
68 maximum lifespan [26]. Notably, a comparative study has highlighted Fisetin as the safest and
69 most potent natural senolytic among the tested compounds [26].

70 To date, research has not determined the effect of senolytics in biological aging measured by
71 molecular biomarkers, such as the length of the telomeres, the proportion of immune cells, and
72 the alteration of DNA Methylation. DNA methylation (DNAm) has emerged as a widely used
73 biomarker for predicting health span and age-related diseases [27], [28]. The widely used first-
74 generation clocks, such as the Hannum clock and Horvath clocks, analyze DNAm patterns to
75 estimate an individual's chronological age [29], [30]. Second-generation clocks, including the
76 DNAmPhenoAge and GrimAge, instead of being trained to predict chronological age, have been

77 trained to predict biological phenotypes, which has increased the hazard ratio prediction of age-
78 related outcomes [31], [32]. Moreover, a third-generation clock, the DunedinPACE, measures
79 the rate of aging rather than providing an overall age estimation [33].

80 Therefore, this study aims to comprehensively assess the impact of senolytic drugs on
81 epigenetic aging through two longitudinal studies to address our research objective. The initial
82 investigation focuses on a combination treatment of Dasatinib and Quercetin, while the
83 subsequent phase incorporates Fisetin into the treatment regimen, allowing for the evaluation of
84 aging effects over a two-year period. This comprehensive approach will provide insights into
85 how senolytic drugs influence epigenetic dynamics and contribute to our understanding of
86 potential interventions in the process of senescence.

87


88 Results

89 **Figure 1** shows the design of the study. 28 individuals were enrolled in our cohort and split
90 across two different studies. In the first study, a total of 19 participants underwent a 6-month
91 treatment period with DQ, and blood samples were taken at baseline, 3 months, and 6 months.
92 The age range of these individuals was between 43.0 and 86.6 (**Table 1**). Following the
93 completion of the initial treatment period, participants remained untreated for a duration of one
94 year. Out of the initial group, 10 participants continued in the trial, while 9 new participants
95 joined the study. In the second trial, all participants underwent a 6-month treatment with DQ and
96 Fisetin, with measurements taken at baseline and 6 months. The average age of the
97 participants in these two studies was 60.9, ranging from 44.5 to 88.0. The percentage of male
98 participants varied across the studies: 57.9% in the DQ study and 42.1% in the DQF study.
99

100 **Table 1. Characteristics of participants in both trials.**

	Dasatinib and Quercetin study	Dasatinib, Quercetin, and Fisetin study
Sample Size	19	19
Age in years, mean (range)	59.6 (43.0 - 86.6)	60.9 (44.5 - 88.0)
Sex, male	11 (57.9%)	8 (42.1%)

101




102
 103 **Figure 1. Timeline diagram for the study design.** In the first study, 19 individuals were treated with
 104 50mg of Dasatinib and 500mg of Quercetin. After one year, the second study started with 10 participants
 105 from the first study and 9 new participants. These individuals were treated with 50mg of Dasatinib, 500mg
 106 of Quercetin, and 500mg of Fisetin.

107
 108
 109
 110 **Impact of senolytic drugs on epigenetic age**

111 To investigate the impact of the combination of DQ and the combination of DQF on epigenetic
 112 age, we assessed biological age using the principal component versions of multiple epigenetic
 113 clocks: the first-generation Horvath pan tissue clock, the Horvath skin and blood clock, and the
 114 Hannum clock; the second generation DNAmPhenoAge and GrimAge; and third generation
 115 DunedinPACE. For these clocks except DunedinPACE, we calculated the epigenetic age
 116 acceleration (EAA) after adjusting the values by age and principal components.

117 We observed that PC Horvath pan tissue EAA significantly increased after 3 months of DQ
 118 treatment ($p\text{-value}=6.7 \cdot 10^{-06}$). However, this increase was followed by a decrease 3 months
 119 later ($p\text{-value}=2.6 \cdot 10^{-4}$), resulting in non-significant differences between the baseline and the 6-
 120 month time point ($p\text{-value}=0.23$) (**Figure 2A; Table 2**). Besides, we detected a significant
 121 increase in this clock after 6 months of DQF treatment ($p\text{-value}=0.017$, see **Table 3**).



122

123 **Figure 2. Boxplot showing the evolution of epigenetic age acceleration (EAA) first-generation**
 124 **clocks in the Dasatinib and Quercetin (DQ) study.** (A) PC Horvath pan tissue EAA. (B) PC Horvath
 125 Skin&Blood EAA. (C) PC Hannum EAA. In the X-axis, the time points of measurements, in the Y axis, the
 126 EAA measure. On the top, the mean values at each time points. The p-values of the paired t-tests are
 127 also displayed in the plots.

128

129 Regarding the other first-generation clocks, PC Horvath Skin&Blood EAA and PC Hannum EAA,
 130 we identified a significant increase following DQ treatment, particularly at the 3-month period
 131 (**Figure 2B-C; Table 2**). However, we did not observe significant changes in EAA after DQF
 132 treatment for these clocks (**Table 3**).

133 For second-generation clocks, we observed a significant increase between baseline and 3-
 134 month test after DQ treatment in PC DNAmPhenoAge (p-value=0.005) and between baseline
 135 and 6-month test (p-value=0.038). On the other hand, PC GrimAge and the third-generation
 136 clock, DunedinPACE, remained stable after the treatment. For DQF treatment, all the second
 137 and third-generation clocks were unchanged.

138 We also evaluated the changes observed by the recently developed IntrinsicClock, as it is agnostic
 139 to immune cell changes that have been shown to influence the reliable quantification of
 140 epigenetic age [34]. However, no significant differences were observed in any of the trials.

141 **Table 2. Statistical analysis for comparing baseline, 3 months, and 6 months epigenetic age**
 142 **acceleration (EAA) in the Dasatinib and Quercetin Study.** The first three columns show the mean
 143 values for each EAA clock at each time point. The next columns have information about the t-test
 144 between baseline and 3-month test, between baseline and 6-month test, and between 3-month and 6-
 145 month tests, respectively.

	Mean			Baseline vs 3-month		Baseline vs 6-month		3-month vs 6-month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value
PC Horvath pan tissue EAA	-1.485	1.254	-0.926	-6.258	$6.7 \cdot 10^{-6}$	-1.230	0.234	4.527	$2.6 \cdot 10^{-4}$
PC Horvath Skin and Blood EAA	-0.625	0.194	-0.064	-2.450	0.025	-1.075	0.297	0.598	0.557
PC Hannum EAA	-1.165	0.474	0.184	-3.622	0.002	-2.561	0.020	0.546	0.592
PC GrimAge EAA	-0.173	-0.179	0.374	0.016	0.988	-1.431	0.170	-1.476	0.157
PC DNAmPheno Age EAA	-1.766	0.891	0.134	-3.237	0.005	-2.240	0.038	0.936	0.362
PC DNAmTL EAA	0.043	-0.024	-0.010	5.098	$7.5 \cdot 10^{-5}$	4.286	$4.4 \cdot 10^{-4}$	-0.931	0.364
DunedinPACE	0.929	0.923	0.927	0.392	0.699	0.112	0.912	-0.230	0.821
Intrinsiclock EAA	0.039	-0.428	0.389	0.714	0.484	-0.499	0.624	-1.235	0.233

147
 148 **Table 3. Statistical analysis for comparing baseline and 6-month epigenetic age acceleration**
 149 **(EAA) in the Dasatinib, Quercetin, and Fisetin Study.** The first two columns show the mean values for
 150 each EAA clock at each time point. The next columns have information about the t-test between baseline
 151 and 6-month test.


	Mean		Baseline vs 6-month	
	Baseline	6-month	T-score	P-value
PC Horvath pan tissue EAA	-0.201	1.607	-2.643	0.017
PC Horvath Skin and Blood EAA	-0.057	0.826	-1.838	0.083
PC Hannum EAA	-0.162	0.853	-1.774	0.093
PC GrimAge EAA	0.101	0.057	0.140	0.890
PC DNAmPhenoAge EAA	-0.033	0.964	-1.094	0.288
PC DNAmTL EAA	0.005	-0.027	1.698	0.107
DunedinPACE	0.937	0.918	1.016	0.323
Intrinsiclock EAA	0.637	-0.637	1.608	0.125

153

154 **Impact of senolytic drugs on DNAm Telomere length and Mitotic Clock Epigenetic**
155 **Methylation Prediction Algorithms**

156 Cells with critically short telomere lengths are also known to undergo senescence once they
157 approach their Hayflick limit [35], therefore we investigated the potential changes due to
158 telomere length using the DNAm predictor for telomere length (DNAmTL) [36]. We found
159 significant alterations in the DQ group, but not in the DQF group. Specifically, we observed a
160 significant decrease in PC DNAm telomere length after the whole treatment (p-value=0.01, see
161 **Figure 3A**), which was even more significant after adjusting by age (p-value= $4.4 \cdot 10^{-4}$, see
162 **Figure 3B**). Importantly, the difference in telomere length acceleration between baseline and 3
163 months was larger and more significant (p-value= $7.5 \cdot 10^{-5}$) than the difference between baseline
164 and 6 months (p-value= $4.4 \cdot 10^{-4}$).

165



166


167 **Figure 3. Boxplot showing the evolution of DNA methylation (DNAm) based telomere length in the**
168 **DQ study.** (A) DNAm telomere length. (B) DNAm telomere length acceleration. In the X-axis, the time
169 points of measurements, in the Y axis, the epigenetic metric. On the top, the mean values at each time
170 point. The p-values of the paired t-tests are also displayed in the plots.

171

172 Mitotic clock metrics were also employed to evaluate relative changes in stem cell replication. At
173 the 3-month mark of DQ treatment, we observed a decrease in both the total number of stem
174 cell divisions and the intrinsic tissue stem cell divisions, although these changes were not
175 statistically significant (p-value=0.22 and p-value=0.22, respectively, see **Figure 4**). However,
176 between 3-month and 6-month points, a significant increase was evident in both mitotic clocks

177 (p-value= $2.4 \cdot 10^{-4}$ and p-value= $7.8 \cdot 10^{-4}$, respectively). In the case of DQF treatment, no
178 significant differences were found between the baseline and the 6-month measurement.

179



180

181 **Figure 4. Boxplot showing the evolution of mitotic clocks in the Dasatinib and Quercetin study.** (A)
182 Total number of stem cell divisions. (B) Intrinsic tissue stem cell division. In the X-axis, the time points of
183 measurements, in the Y axis, the number of divisions. On the top, the mean values at each time point.
184 The p-values of the paired t-tests are also displayed in the plots.

185

186 Impact of senolytic drugs on whole blood immune cell composition

187 We utilized EpiDISH (2023) to quantify 12 different immune cell subsets and assess changes
188 within these subsets. During the 6-month period of DQ treatment, significant alterations were
189 observed in CD4T Naive cells, B Naive cells, and monocytes (**Table 4**). The most notable and
190 significant change was in CD4T Naive Cells, which exhibited a slight decrease at the 3-month
191 mark (p-value=0.628) and experienced a more substantial decline between the 3 and the 6-
192 month marks (p-value=0.029). B Naive cells displayed an insignificant increase for the global
193 treatment (p-value=0.059), but we observed a significant increase between 3 and 6 months (p-
194 value=0.001). Monocytes showed a global increase after 6 months of treatment (p-value=0.003)
195 that was characterized by a significant decrease at 3 months (p-value=0.035) followed by a
196 significant increase between 3 and 6 months (p-value= $3.0 \cdot 10^{-5}$). Conversely, CD4T Memory,
197 CD8T Naive, CD8T Memory, B Memory, basophil, regulatory T cells, eosinophil, Natural Killer,
198 and Neutrophil did not exhibit significant changes.

199 **Table 4. Statistical analysis for comparing baseline, 3 months, and 6 months immune cell**
 200 **proportions in the Dasatinib and Quercetin Study.** The first three columns show the mean values for
 201 each immune cell proportion at each time point. The next columns have information about the t-test
 202 between baseline and 3-month test, between baseline and 6-month test, and between 3-month and 6-
 203 month tests, respectively.
 204

	Mean			Baseline vs 3-month		Baseline vs 6-month		3-month vs 6-month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value
CD4T naive cells	0.077	0.074	0.060	0.493	0.628	2.228	0.039	2.364	0.029
Basophiles	0.020	0.021	0.020	-1.147	0.266	-0.408	0.688	0.439	0.666
CD4T memory cells	0.084	0.081	0.079	0.535	0.599	0.639	0.531	0.410	0.686
B memory cells	0.019	0.017	0.019	1.287	0.214	-0.457	0.653	-1.380	0.184
B naive cells	0.040	0.035	0.046	1.611	0.125	-2.018	0.059	-3.907	0.001
T regulatory cells	0.005	0.007	0.008	-0.978	0.341	-1.946	0.067	-0.842	0.411
CD8T memory cells	0.051	0.052	0.049	-0.290	0.775	0.359	0.724	0.650	0.524
CD8T naive cells	0.025	0.028	0.026	-1.354	0.193	-0.456	0.654	0.607	0.552
Eosinophiles	0.009	0.009	0.005	0.306	0.763	1.400	0.178	1.036	0.314
Natural Killer	0.044	0.047	0.048	-0.696	0.495	-1.046	0.309	-0.339	0.739
Neutrophiles	0.564	0.575	0.556	-0.612	0.548	0.309	0.761	0.966	0.347
Monocytes	0.062	0.053	0.082	2.282	0.035	-3.415	0.003	-5.527	3.0·10 ⁻⁵

205
 206
 207 Regarding the impact of DQF on immune cells, B Naive cells (Bnv) demonstrated a significant
 208 decrease after 6 months ($p\text{-value}=3.0\cdot 10^{-4}$), which contrasts with the observations from DQ
 209 treatment. No significant changes were observed in the proportions of other immune cell
 210 subsets (**Table 5**).

211
 212
 213
 214
 215


216 **Table 5. Statistical analysis for comparing baseline and 6-month immune cell proportions in the**
 217 **Dasatinib, Quercetin, and Fisetin Study.** The first two columns show the mean values for each immune
 218 cell proportion at each time point. The next columns have information about the t-test between baseline
 219 and 6-month test.
 220

	Mean		Baseline vs 6-month	
	Baseline	6-month	T-score	P-value
CD4T naive cells	0.065	0.063	0.200	0.844
Basophiles	0.014	0.013	0.507	0.618
CD4T memory cells	0.081	0.089	-0.926	0.367
B memory cells	0.017	0.015	1.122	0.277
B naive cells	0.040	0.024	4.470	3.0·10 ⁻⁴
T regulatory cells	0.006	0.004	2.069	0.053
CD8T memory cells	0.063	0.058	0.950	0.354
CD8T naive cells	0.020	0.017	1.202	0.245
Eosinophiles	0.011	0.011	-0.009	0.993
Natural Killer	0.055	0.048	1.620	0.123
Neutrophils	0.569	0.597	-1.336	0.198
Monocytes	0.060	0.062	-0.421	0.679

221

222

223 Since most of the epigenetic clocks, especially the first-generation clocks, are dependent on
 224 immune subsets, we calculated the correlation between the EAA metrics and the immune cells
 225 proportions. As expected, we did not observe significant correlations between IntrinsicClock and
 226 immune cells. However, we observed high correlations between the other clocks and most of
 227 the immune cells (**Figure 5**). Thus, we decided to calculate immune EAA adjusting EAA values
 228 by all the immune cells that were significantly associated to the clocks (CD4T naive and
 229 memory cells, B naive and memory cells, CD8T naive and memory cells, natural killers, and
 230 neutrophils) and see whether the trends in first-generation clocks after DQ treatment were
 231 maintained. We found that the significance and direction of the associations were not modified
 232 after adjusting by immune cells, indicating that the increase of epigenetic age after DQ
 233 treatment was not due to the alteration of immune cell subsets (**Supplementary Figure S1**).



234

235 **Figure 5. Correlation between epigenetic clocks and immune cell types.** The size of the dots is
 236 proportional to the correlation value, being blue a positive correlation and red a negative correlation.

237

238 **Impact of senolytic drugs on whole-genome DNA methylation**

239 We also assessed global modification of DNAm in those individuals who were treated with DQ
 240 and those with DQF. To this end, we performed an Epigenome-wide association study (EWAS)
 241 comparing the methylation levels for all the CpG sites in the genome at different timepoints in
 242 each trial (**Supplementary Table S1**).

243 The first EWAS was performed between baseline and 3 months of DQ treatment. In this case,
 244 we identified 11 CpG sites differentially methylated, 4 of them hypermethylated and 7
 245 hypomethylated after 3 months. These probes were mapped to 8 genes. Among them, *TGIF1*,
 246 *SORBS2*, and *ZNF768* were implicated in senescence [37]–[39]. Using a less restrictive
 247 threshold of p-value lower than $1 \cdot 10^{-4}$, we performed an enrichment analysis. Among the 305
 248 probes identified, we found three enriched processes highly related with senescence, such as
 249 glycolic process, vesicle recycling and endocytosis, and cytoskeletal organization [40]–[42].

250 Second, we evaluated the differences at global methylation between baseline and 6 months
 251 after DQ treatment. In this case, we only saw 2 CpG sites differentially methylated with an

252 adjusted p-value lower than 0.05. One of them was hypermethylated and the other
253 hypomethylated after a period of 6 months. The GREAT analysis was performed with the 475
254 CpG sites with a nominal p-value lower than $1 \cdot 10^{-4}$. Although multiple gene ontology terms were
255 identified as enriched, none of them were directly associated with aging or senescence.

256 Finally, when we compared the methylation levels between baseline and 6 months after DQF
257 treatment, we identified 208 significant probes. Among them, approximately 50% were
258 hypomethylated and 50% were hypermethylated. The GREAT analysis was performed using
259 556 probes and revealed multiple enriched pathways associated with senescence, such as
260 epithelial cell proliferation, platelet dense granule membrane, cell junction, and positive
261 regulation of cardiac muscle cell apoptotic process [43]–[47].

262

263 **Clinical and DNAm Proteomic Surrogate Analysis**

264 The major hypothesized mechanism for the negative impacts of senescence is through the
265 increased senescence-associated secretory phenotypes (SASP) which lead to high
266 inflammatory cytokine signaling from senescent cells in a paracrine fashion. As an alternative to
267 robust clinical lab measurements of inflammatory mediators, we used methylation risk scores
268 surrogates to predict and quantify predicted changes in circulating proteomic markers [48]. The
269 quantification of these markers and the comparison between the different timepoints are
270 included in **Supplementary Table S2**).

271 We paid special attention to inflammation and inflammatory proteomic EpiScore analysis and
272 these are listed in **Table 6**. In this analysis, we see some increased inflammatory mediators at 3
273 months which decrease from the 3 to 6-month timepoints. These inflammatory associated
274 proteins include CRP, CXCL9, CXCL11, CCL17, and TGF-alpha. We see opposite trends with
275 other inflammation associated markers such as Complement C4 and Complement C5a. Many
276 inflammatory mediators for the innate adaptive immune system were not registered as
277 significant in this analysis.

278

279

280

281

282

283

284

285

286

287

288 **Table 6. Inflammation and inflammatory proteomic EpiScore analysis between baseline, 3-month**
 289 **test, and 6-month test in the Dasatinib and Quercetin (DQ) trial.** The first three columns show the
 290 mean values for each protein methylation risk score (MRS) at each time point. The next columns have
 291 information about the t-test between baseline and 3-month test, between baseline and 6-month test, and
 292 between 3-month and 6-month tests, respectively.
 293

	Mean			Baseline vs 3-month		Baseline vs 6-month		3-month vs 6-month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value
CCL11	-0.007	-0.007	-0.004	0.071	0.944	-2.94	0.009	-3.97	0.001
CCL17	-0.434	-0.428	-0.435	-3.306	0.004	1.062	0.302	3.614	0.002
CCL18	-0.15	-0.15	-0.148	0.002	0.998	-1.443	0.166	-1.722	0.102
CCL21	-0.127	-0.128	-0.127	1.449	0.165	0.06	0.953	-1.473	0.158
CCL22	-0.066	-0.065	-0.064	-0.428	0.674	-3.241	0.005	-3.269	0.004
Complement C4	0.032	0.031	0.033	2.923	0.009	-1.723	0.102	-4.513	2.7·10 ⁻⁴
Complement C5a	0.155	0.148	0.158	3.721	0.002	-2.268	0.036	-6.877	2.0·10 ⁻⁵
Complement C9	-0.013	-0.012	-0.011	-0.545	0.592	-0.751	0.462	-0.229	0.822
CRP	-0.114	-0.107	-0.115	-4.888	1.2·10 ⁻⁴	0.979	0.34	4.679	1.9·10 ⁻⁴
CXCL10 soma	-0.345	-0.338	-0.343	-2.939	0.009	-0.966	0.347	1.911	0.072
CXCL11 soma	-0.053	-0.05	-0.054	-3.291	0.004	1.282	0.216	5.23	5.7·10 ⁻⁵
CXCL9	-0.034	-0.031	-0.037	-3.347	0.004	2.728	0.014	5.132	7.0·10 ⁻⁵
Interleukin 19	-0.002	-0.005	-0.005	1.064	0.302	1.241	0.231	0.188	0.853
TGF alpha	0.021	0.026	0.018	-2.842	0.011	1.29	0.213	3.989	0.001
TNFRSF1B	-0.106	-0.104	-0.105	-1.898	0.074	-1.028	0.317	0.525	0.606
Relative IL6 Level	-0.079	-0.086	-0.041	0.501	0.622	-2.495	0.023	-3.292	0.004

294

295

296

297 Discussion

298 Overall, our findings indicate that the administration of senolytic drugs Dasatinib and Quercetin
299 significantly increases biological age measured by first generation clocks. The only 2nd
300 generation clock to show an increase was DNAmPhenoAge. However, we see no significant
301 change in second and third-generation clocks such as GrimAge and DunedinPACE or any
302 significant changes with the addition of Fisetin to the protocol (DQF treatment).

303 The increase in DNAmPhenoAge is different in trend from the other phenotypically trained
304 clocks but is not surprising as this clock has previously been described as a hybrid between first
305 and second-generation clocks. Unlike GrimAge and DunedinPoAm, the dependent variable
306 used for training DNAmPhenoAge, also included chronological age. While GrimAge included
307 observed age in its derivation on the other side of the equation—as a predictor along with
308 DNAm—essentially adjusting out its effects. This similarity is further described by its module
309 composition which reflects similarity to first generation trained chronological clocks [49].

310 The biological aging impacts effects of this analysis are difficult to analyze. While, the link
311 between cellular senescence and aging is indisputable [50]. The differential analysis of these
312 clocks limits our interpretation of their clinical significance.

313 Previous studies have shown that the first-generation clocks, such as the Skin&blood clock, will
314 increase with cell passage and time in cell culture. This increase was shown irrespective of cells
315 which have human telomerase reverse transcriptase (hTERT) expressed and thus didn't enter
316 replicative senescence or have telomere attrition which suggest that these first-generation
317 clocks are measuring a process separate from either senescence or telomere attrition [51]. This
318 suggests that epigenetic age clocks might not do a good job in measuring the process of
319 senescence or the biological impact of senescence.

320 However, the non-significant change in 2nd and 3rd generation clocks such as GrimAge and
321 DunedinPACE is also informative. 2nd and 3rd generation clocks, trained to phenotypes of
322 aging, are more prone to capture the underlying biology of aging since these are trained to
323 biomarkers of the biological aging process and not just correlating CpGs to chronological age. It
324 is plausible that the significant biological age increases that are seen in the first-generation
325 clocks, and DNAmPhenoAge, might be accelerated due to the age correlated CpG locations
326 and not the underlying biological relevant impacts since the more predictive, and more biological
327 associated, 2nd and 3rd generation clocks are not showing the same increase. Thus, while
328 neither generation of clocks are showing improvement with senolytic treatment, the increases in
329 the 1st generation clocks are less reliable for predicting the phenotypic outcomes and thus
330 should be interpreted carefully.

331 This ability for different generations of clocks to reflect different interventional change is not
332 new. In previous DNAm interventional studies such as the CALERIE study, we see that caloric
333 restriction only displayed significant aging changes with DunedinPACE, yet didn't show
334 significance with any other clock [52].

335 Another confounding variable which limits our ability to establish biological aging significance is
336 the significant changes in CD4T and CD8T Naive cells, B Naive cells, and monocytes. Immune
337 cell changes with aging have been a large confounding error in previous DNAm clocks. For
338 instance, previous studies have shown that human naive CD8+ T cells can exhibit an epigenetic
339 age 15–20 years younger than effector memory CD8+ T cells from the same individual. This
340 means that previous epigenetic clocks measure two independent variables, aging and immune
341 cell composition [53]. To analyze if immune changes were responsible for the first-generation
342 epigenetic clock acceleration, we calculated immune EAA and adjusted by all the immune cells
343 that were significantly associated to the clocks (CD4T naive and memory cells, B naive and
344 memory cells, CD8T naive and memory cells, natural killers, and neutrophils). We found that the
345 significance and direction of the associations were not modified after adjusting by immune cells,
346 indicating that the increase of epigenetic age after DQ treatment was not due to the modulation
347 of immune cell subsets but representing an increase due to the CpG inclusion and weights of
348 the clocks themselves.

349 Furthermore, we also analyzed the IntrinsicClock to assess the relationship of immune cell
350 subtypes. The IntrinsicClock was created to be independent of immune cell subset changes. And
351 created through an analysis of the age-related changes in independent cell types. This clock
352 showed no significant change in any of the treatment arms. This might be due to the unique
353 construction method for the IntrinsicClock. IntrinsicClock was generated via the deliberate removal of
354 CpGs that were characteristic of naïve cells. It is possible that senolytic treatment is affecting a
355 subset of CpGs that were removed in the construction of the IntrinsicClock that are more
356 correlated to general properties of naïve cells (quiescence, etc.) rather than those that represent
357 immune cell type composition specifically.

358 The major hypothesized mechanism for the negative impacts of senescence is through the
359 increased senescence-associated secretory phenotypes (SASP) which lead to high
360 inflammatory cytokine signaling from senescent cells in a paracrine fashion. Although SASP
361 proteins were not measured directly in this study, we used DNA methylation risk scores for
362 protein surrogates to analyze changes in common SASP proteins. In some cases, these
363 methylation risk scores have been shown to have better resolution and connection to outcomes
364 than traditional measures. For instance, the EpiScore for C-Reactive protein has shown age-
365 related associations in cohorts which were not seen with log(CRP) clinical measures and
366 association to cognitive function and brain MRIs [54]. Looking at these methylation risk scores in
367 our longitudinal data, we see some interesting trends of increased inflammatory mediators at 3
368 months which decrease from the 3-6 month timepoints. These inflammatory associated proteins
369 include CRP, CXCL9, CXCL11, CCL17, and TGF-alpha. We see opposite trends with other
370 inflammation associated markers such as Complement C4 and Complement C5a. The accuracy
371 of the EpiScore protein predictions to measured proteins is still low. Thus, the changes we see
372 here are limited by accuracy of the prediction. CRP, which is the most validated of the
373 proteomic EpiSign scores, shows decreases at 3 months and increases at 6 months which
374 might suggest duration of senolytic therapy might impact the phenotypic outcomes.
375 Furthermore, the treatment impacts on the SASP might also indicate a plausible explanation for

376 the differences in age accelerations between the first generation IntrinsicClock and other first-
377 generation clocks. SASP-related CpG sites would be differentially methylated in naïve T cells
378 and thus removed from construction of the IntrinsicClock but not Horvath, Hannum, or PhenoAge.
379 Clocks.

380 Together, our findings suggest that 1st generation clocks are insufficient tools to quantify the
381 impact of senolytic therapies. Additionally, second generation clocks still remain largely
382 unchanged with Dasatinib and Quercetin use and other markers are needed to measure the
383 physiologic impact of senolytic treatments. In either instance, our findings reemphasize the
384 importance of developing new biomarkers which can quantify senescence and impact to aging
385 phenotypes.

386 Strengths of the present study include its prospective longitudinal design, the duration of
387 longitudinal measures, the standardized and batch normalized epigenetic data, and
388 comprehensive inclusion of novel and complementary epigenetic age measures that were
389 repeatedly collected.

390 There are also some important limitations. First, was the limitation of small sample size and the
391 lack of a control group. Having epigenetic methylation changes in the control group and a large
392 sample size may have improved statistical power to detect small effects. Likewise, the sample
393 size did not allow a rigorous analysis of individual CpG sites with correction for multiple
394 comparisons. Future, larger studies should replicate the present results and extend them by
395 examining other epigenetic clocks and individual CpG sites with appropriate corrections for
396 multiple testing.

397 Secondly, epigenetic aging markers were not supplemented with classical blood measurements
398 or classical phenotypic markers of aging and thus, it is possible that some unmeasured
399 confounders biased our results. However, age acceleration was independent of potential
400 confounders including chronological age and sex.

401 Finally, DNA methylation was measured in blood samples only. As senescence is different in
402 every tissue type, blood based DNAm data might not capture the physiologic impact of senolytic
403 therapy and future studies in tissue specific analysis might provide more insight.

404 Future studies can improve on our limitations by including large sample size, additional clinical
405 biomarkers of inflammation and senescence, and incorporate analysis into tissues more
406 associated with senescence related aging phenotypes. We hope this data can be reanalyzed as
407 new senolytic DNA methylation analysis tools become available.

408

409

410 Materials and methods

411 **Study participants and senolytic administration**

412 For the evaluation of DQ treatment upon epigenetic age, 19 study participants were accrued
413 from November 2020 to December 2020 at the Institute for Hormonal Balance, Orlando. **Table 1**
414 shows the demographic and clinical characteristics of these participants. Adults aged 40 and
415 older able to comply with treatment plan and laboratory tests were included. Individuals with
416 neoplastic cancer within 5 years prior to screening, immune disease, viral illness, cardiovascular
417 or cerebrovascular disease, ischemic attack in the last 6 months, hepatitis or HIV, Body mass
418 index higher than 40kg/m², active infection, or previously used DQ were excluded. Informed
419 consent was obtained from study participants. The FDA registered IRB (Institute for
420 Regenerative and Cellular Medicine) approved this study, which is registered at
421 ClinicalTrials.gov (NCT04946383) and which is an ongoing clinical trial to determine the
422 effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate.
423 The treatment comprised 500mg Quercetin and 50mg Dasatinib oral capsules on Monday,
424 Tuesday, and Wednesday (3 days in a row) per month for the duration of 6 months. It is worth
425 mentioning that three subjects stopped the treatment after 3 months due to nausea, prostate
426 cancer diagnosis, and concern about the drug, respectively.

427 For the evaluation of DQF treatment, all the participants from the first study were invited to join
428 and new participants were recruited from June 2022 to July 2022 at the Institute for Hormonal
429 Balance, Orlando. From the previous study, 10 participants joined this study, and 9 participants
430 were newly recruited. The same inclusion and exclusion criteria were followed as in the DQ
431 study. In this case, the treatment consisted of the same dosage and timeline as in the DQ
432 treatment but included 500 mg of Fisetin oral capsules on Monday, Tuesday, and Wednesday
433 (3 days in a row) per month for the duration of 6 months. Moreover, 8 participants got a
434 strawberry based Fisetin and 11 got a non-strawberry based Fisetin.

435

436 **DNA methylation assessment**

437 Peripheral whole blood samples were obtained using the lancet and capillary method and
438 immediately mixed with lysis buffer to preserve the cells. DNA extraction was performed, and
439 500 ng of DNA was subjected to bisulfite conversion using the EZ DNA Methylation kit from
440 Zymo Research, following the manufacturer's protocol. The bisulfite-converted DNA samples
441 were then randomly allocated to designated wells on the Infinium HumanMethylationEPIC
442 BeadChip. The samples were amplified, hybridized onto the array, and subsequently stained.
443 After washing steps, the array was imaged using the Illumina iScan SQ instrument to capture
444 raw image intensities, enabling further analysis.

445 *Minfi* R package was used for the pre-processing of DNAm data. We pre-processed all the
446 samples from the different studies together to remove batch effects. In the sample quality

447 control, we removed those samples with aberrant methylation levels and with background signal
448 levels (mean p-value higher than 0.05). We also discarded those probes with background signal
449 following the same threshold. We further normalized the methylation values using the Genome-
450 wide Median Normalization (GMQN) and the Beta Mixture Quantile (BMIQ) methods. Finally, we
451 imputed the missing values using the k-nearest neighbors (knn) algorithm. Finally, we used a
452 12-cell immune deconvolution method developed by Zheng et al to estimate cell type
453 proportions. We chose this method because in previous analysis we saw this has R^2 of 0.96 and
454 above to immune cell subsets measured by RNA-seq and flow cytometry [55].

455

456 **Statistical analyses and reproducibility**

457 DNA methylation clocks and related measures

458 We used DNAm data to calculate a series of measures broadly known as epigenetic clocks. We
459 computed four clocks designed to predict the chronological age of the donor, Horvath Pan
460 Tissue, Horvath Skin and Blood, and Hannum; two clocks designed to predict mortality, the
461 DNAmPhenoAge and GrimAge clocks; a clock to measure telomere length, DNAmTL [36]; two
462 clock designed to measure mitotic age, total stem cell divisions (tnsc) and intrinsic tissue stem
463 cell division (irS) [56]; a DNAm measure of the rate of deterioration in physiological integrity, the
464 DunedinPACE; and a clock to measure chronological age but not dependent on immune cells,
465 the IntrinsicClock.

466 To calculate the principal component-based epigenetic clock for the Horvath multi-tissue clock,
467 Hannum clock, DNAmPhenoAge clock, GrimAge clock, and telomere length we used the
468 custom R script available via GitHub (<https://github.com/MorganLevineLab/PC-Clocks>). Non-
469 principal component-based (non-PC) Horvath, Hannum, and DNAmPhenoAge epigenetic
470 metrics were calculated using the *methyAge* function in the *ENMix* R package. The pace of
471 aging clock, DunedinPACE, was calculated using the *PACEProjector* function from the
472 *DunedinPACE* package available via GitHub (<https://github.com/danbelsky/DunedinPACE>). The
473 mitotic clocks were calculated using the *epiTOC2* function from the *meffonym* package. Finally,
474 the IntrinsicClock was calculated as described elsewhere [53].

475 To calculate the EAA of multiple clocks, we fit a regression model between the chronological
476 age of the individuals and the different epigenetic age measures. We also included the batch
477 PCs as a fixed effect as a way to control for potential batch effects. This methodology of
478 incorporating PCs in EAA calculations was previously described in Joyce et al.

479

480 Differentially methylated loci analysis

481 The epigenome-wide association study (EWAS) was performed using the *limma* Bioconductor
482 package. We performed a differential mean analysis on different timepoints to see whether the

483 treatment was associated with changes at specific loci. Based on the available covariates, we
484 adjusted all the regression models by sex, age, batch effect, and three principal components.
485 We also set as random effect the participant ID. For each timepoint comparison, we fitted
486 models

$$487 \quad E_j = \alpha_j + \beta_j S + \sum \gamma_r C_r + \epsilon_j \quad (1)$$

488 where E_j denotes the methylation level vector across individuals at probe j ($j = 1, \dots, 866836$), S
489 is the time point with its associated effect, β_j , C_r is the r adjusting covariate and its effect γ_r , and
490 ϵ_j is the noise that follows the distribution of methylation levels with mean 0. Adjusted P-values
491 were calculated using FDR correction for considering multiple comparisons. The inflation or
492 deflation of P-values across the methylome was assessed with Q-Q plots and lambda values.
493 We selected as significant probes those with FDR lower than 0.05 after correcting for multiple
494 comparisons.

495 We next used GREAT to understand the functional relevance of the differentially methylated loci
496 (DML) with a nominal p-value lower than $1 \cdot 10^{-4}$. The GREAT software will compare genomic
497 features against the genes of interest in order to run Gene Ontology (GO) analysis. This
498 software looks at the number of DMLs which overlap to the promoter and enhancer regions to
499 run a binomial enrichment analysis of identifying overrepresented/enriched GO terms.

500

501 Author contributions

502 EL performed patient recruitment, clinical management, and sample procurement. NC and VD
503 performed methylation preprocessing, data analysis, and statistical analysis. EV and AT
504 analyzed IntronClock data. LN and MC provided immune cell subset analysis. TM conducted
505 methylation laboratory analysis. HW, AL, LT, LL, and RS helped with study design, manuscript
506 drafting, and submission.

507

508 Acknowledgements

509 We are grateful to all participants and researchers who took part in this study.

510

511 Conflicts of interest

512 NC, VBD, RS, HW, AL, LT, and TLM are employees of TruDiagnostic.

513

514

515

516 Ethical Statement

517 The study involving human participants was reviewed and approved by the Institute for
518 Regenerative and Cellular Medicine. The participants provided informed consent to participate
519 in this study.

520

521 Funding

522 TruDiagnostic has provided funding for data analysis and IRB funding. The Institute for
523 Hormonal Balance provided all other costs associated with testing and patient recruitment.

524

525 Supplementary Materials

526 Figure S1. Boxplot showing the evolution of epigenetic age acceleration (EAA) first-generation
527 clocks after adjusting by immune cells in the Dasatinib and Quercetin (DQ) study.

528 Table S1. Differentially methylated loci for Dasatinib and Quercetin (DQ) treatment and
529 Dasatinib, Quercetin, and Fisetin (DQF) treatment.

530 Table S2. Statistical analysis for comparing baseline, 3 month, and 6 month Marioni markers
531 proportions in the Dasatinib and Quercetin Study.

532

533 References




- 534 [1] T. Tchkonina, Y. Zhu, J. Van Deursen, J. Campisi, and J. L. Kirkland, "Cellular senescence
535 and the senescent secretory phenotype: therapeutic opportunities," *J Clin Invest*, vol.
536 123, no. 3, pp. 966–972, Mar. 2013, doi: 10.1172/JCI64098.
- 537 [2] L. Hayflick, "The limited in vitro lifetime of human diploid cell strains," *Exp Cell Res*, vol.
538 37, no. 3, pp. 614–636, Mar. 1965, doi: 10.1016/0014-4827(65)90211-9.
- 539 [3] J. Campisi and F. D'Adda Di Fagagna, "Cellular senescence: when bad things happen to
540 good cells," *Nature Reviews Molecular Cell Biology* 2007 8:9, vol. 8, no. 9, pp. 729–740,
541 Sep. 2007, doi: 10.1038/nrm2233.
- 542 [4] C. Kang, "Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular
543 Senescence for Delaying Aging and Age-Related Diseases.," *Mol Cells*, vol. 42, no. 12,
544 pp. 821–827, Dec. 2019, doi: 10.14348/molcells.2019.0298.
- 545 [5] V. Gorgoulis *et al.*, "Cellular Senescence: Defining a Path Forward," *Cell*, vol. 179, no. 4.
546 Cell Press, pp. 813–827, Oct. 31, 2019. doi: 10.1016/j.cell.2019.10.005.



- 547 [6] S. He and N. E. Sharpless, "Senescence in Health and Disease," *Cell*, vol. 169, no. 6, pp.
548 1000–1011, Jun. 2017, doi: 10.1016/j.cell.2017.05.015.
- 549 [7] M. Xu *et al.*, "Senolytics improve physical function and increase lifespan in old age," *Nat*
550 *Med*, vol. 24, no. 8, pp. 1246–1256, Aug. 2018, doi: 10.1038/s41591-018-0092-9.
- 551 [8] M. Xu *et al.*, "Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in
552 Mice," *J Gerontol A Biol Sci Med Sci*, p. glw154, Aug. 2016, doi: 10.1093/gerona/glw154.
- 553 [9] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, "The Hallmarks
554 of Aging," *Cell*, vol. 153, no. 6, pp. 1194–1217, Jun. 2013, doi:
555 10.1016/j.cell.2013.05.039.
- 556 [10] J. Guo *et al.*, "Aging and aging-related diseases: from molecular mechanisms to
557 interventions and treatments," *Signal Transduct Target Ther*, vol. 7, no. 1, p. 391, Dec.
558 2022, doi: 10.1038/s41392-022-01251-0.
- 559 [11] B. K. Kennedy *et al.*, "Geroscience: Linking Aging to Chronic Disease," *Cell*, vol. 159, no.
560 4, pp. 709–713, Nov. 2014, doi: 10.1016/j.cell.2014.10.039.
- 561 [12] J. L. Kirkland and T. Tchkonja, "Senolytic drugs: from discovery to translation," *J Intern*
562 *Med*, vol. 288, no. 5, pp. 518–536, Nov. 2020, doi: 10.1111/joim.13141.
- 563 [13] A. Gnoni, I. Marech, N. Silvestris, A. Vacca, and V. Lorusso, "Dasatinib: An Anti-Tumour
564 Agent via Src Inhibition," *Curr Drug Targets*, vol. 12, no. 4, pp. 563–578, Apr. 2011, doi:
565 10.2174/138945011794751591.
- 566 [14] M. Ichwan *et al.*, "Apple Peel and Flesh Contain Pro-neurogenic Compounds," *Stem Cell*
567 *Reports*, vol. 16, no. 3, pp. 548–565, Mar. 2021, doi: 10.1016/j.stemcr.2021.01.005.
- 568 [15] N. Khan, D. N. Syed, N. Ahmad, and H. Mukhtar, "Fisetin: A Dietary Antioxidant for
569 Health Promotion," *Antioxid Redox Signal*, vol. 19, no. 2, pp. 151–162, Jul. 2013, doi:
570 10.1089/ars.2012.4901.
- 571 [16] E. O. Wissler Gerdes, Y. Zhu, T. Tchkonja, and J. L. Kirkland, "Discovery, development,
572 and future application of senolytics: theories and predictions," *FEBS J*, vol. 287, no. 12,
573 pp. 2418–2427, Jun. 2020, doi: 10.1111/febs.15264.
- 574 [17] L. J. Hickson *et al.*, "Senolytics decrease senescent cells in humans: Preliminary report
575 from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease,"
576 *EBioMedicine*, vol. 47, pp. 446–456, Sep. 2019, doi: 10.1016/j.ebiom.2019.08.069.
- 577 [18] M. T. Islam *et al.*, "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue
578 inflammation, and ameliorate metabolic function in old age," *Aging Cell*, vol. 22, no. 2,
579 Feb. 2023, doi: 10.1111/ace1.13767.
- 580 [19] S. Ijima *et al.*, "Fisetin reduces the senescent tubular epithelial cell burden and also
581 inhibits proliferative fibroblasts in murine lupus nephritis," *Front Immunol*, vol. 13, Nov.
582 2022, doi: 10.3389/fimmu.2022.960601.
- 583 [20] W. S. Hambright *et al.*, "The Senolytic Drug Fisetin Attenuates Bone Degeneration in the
584 Zmpste24^{-/-} Progeria Mouse Model," *J Osteoporos*, vol. 2023, pp. 1–12, Feb. 2023, doi:
585 10.1155/2023/5572754.
- 586 [21] M. J. Schafer *et al.*, "Cellular senescence mediates fibrotic pulmonary disease," *Nat*
587 *Commun*, vol. 8, no. 1, p. 14532, Feb. 2017, doi: 10.1038/ncomms14532.



- 588 [22] E. J. Novais *et al.*, “Long-term treatment with senolytic drugs Dasatinib and Quercetin
589 ameliorates age-dependent intervertebral disc degeneration in mice,” *Nat Commun*, vol.
590 12, no. 1, p. 5213, Sep. 2021, doi: 10.1038/s41467-021-25453-2.
- 591 [23] A. D. Ruggiero *et al.*, “Long-term dasatinib plus quercetin effects on aging outcomes and
592 inflammation in nonhuman primates: implications for senolytic clinical trial design,”
593 *Geroscience*, Jun. 2023, doi: 10.1007/s11357-023-00830-5.
- 594 [24] N. S. Gasek, G. A. Kuchel, J. L. Kirkland, and M. Xu, “Strategies for targeting senescent
595 cells in human disease,” *Nat Aging*, vol. 1, no. 10, pp. 870–879, Oct. 2021, doi:
596 10.1038/s43587-021-00121-8.
- 597 [25] N. Afroze *et al.*, “Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative
598 Stress and Inflammation in Human Cancer Cells, HeLa,” *Int J Mol Sci*, vol. 23, no. 3, p.
599 1707, Feb. 2022, doi: 10.3390/ijms23031707.
- 600 [26] M. J. Yousefzadeh *et al.*, “Fisetin is a senotherapeutic that extends health and lifespan,”
601 *EBioMedicine*, vol. 36, pp. 18–28, Oct. 2018, doi: 10.1016/j.ebiom.2018.09.015.
- 602 [27] C. G. Bell *et al.*, “DNA methylation aging clocks: challenges and recommendations,”
603 *Genome Biol*, vol. 20, no. 1, p. 249, Dec. 2019, doi: 10.1186/s13059-019-1824-y.
- 604 [28] T. Bergsma and E. Rogaeva, “DNA Methylation Clocks and Their Predictive Capacity for
605 Aging Phenotypes and Healthspan,” *Neurosci Insights*, vol. 15, p. 263310552094222,
606 Jan. 2020, doi: 10.1177/2633105520942221.
- 607 [29] S. Horvath, “DNA methylation age of human tissues and cell types,” *Genome Biol*, vol.
608 14, no. 10, p. R115, 2013, doi: 10.1186/gb-2013-14-10-r115.
- 609 [30] G. Hannum *et al.*, “Genome-wide Methylation Profiles Reveal Quantitative Views of
610 Human Aging Rates,” *Mol Cell*, vol. 49, no. 2, pp. 359–367, Jan. 2013, doi:
611 10.1016/j.molcel.2012.10.016.
- 612 [31] M. E. Levine *et al.*, “An epigenetic biomarker of aging for lifespan and healthspan,” *Aging*,
613 vol. 10, no. 4, pp. 573–591, Apr. 2018, doi: 10.18632/aging.101414.
- 614 [32] A. T. Lu *et al.*, “DNA methylation GrimAge strongly predicts lifespan and healthspan,”
615 *Aging*, vol. 11, no. 2, pp. 303–327, Jan. 2019, doi: 10.18632/aging.101684.
- 616 [33] D. W. Belsky *et al.*, “DunedinPACE, a DNA methylation biomarker of the pace of aging,”
617 *Elife*, vol. 11, Jan. 2022, doi: 10.7554/eLife.73420.
- 618 [34] T. H. Jonkman *et al.*, “Functional genomics analysis identifies T and NK cell activation as
619 a driver of epigenetic clock progression,” *Genome Biol*, vol. 23, no. 1, p. 24, Dec. 2022,
620 doi: 10.1186/s13059-021-02585-8.
- 621 [35] S. Victorelli and J. F. Passos, “Telomeres and Cell Senescence - Size Matters Not,”
622 *EBioMedicine*, vol. 21, pp. 14–20, Jul. 2017, doi: 10.1016/j.ebiom.2017.03.027.
- 623 [36] A. T. Lu *et al.*, “DNA methylation-based estimator of telomere length,” *Aging*, vol. 11, no.
624 16, pp. 5895–5923, Aug. 2019, doi: 10.18632/aging.102173.
- 625 [37] B. J. Zerlanko, L. Bartholin, T. A. Melhuish, and D. Wotton, “Premature Senescence and
626 Increased TGF β Signaling in the Absence of Tgif1,” *PLoS One*, vol. 7, no. 4, p. e35460,
627 Apr. 2012, doi: 10.1371/journal.pone.0035460.

- 628 [38] M. Liesenfeld *et al.*, "SORBS2 and TLR3 induce premature senescence in primary
629 human fibroblasts and keratinocytes," *BMC Cancer*, vol. 13, p. 507, Oct. 2013, doi:
630 10.1186/1471-2407-13-507.
- 631 [39] R. Villot *et al.*, "ZNF768 links oncogenic RAS to cellular senescence," *Nat Commun*, vol.
632 12, no. 1, Dec. 2021, doi: 10.1038/S41467-021-24932-W.
- 633 [40] C. D. Wiley and J. Campisi, "From Ancient Pathways to Aging Cells-Connecting
634 Metabolism and Cellular Senescence.," *Cell Metab*, vol. 23, no. 6, pp. 1013–1021, Jun.
635 2016, doi: 10.1016/j.cmet.2016.05.010.
- 636 [41] E.-Y. Shin, N.-K. Soung, M. A. Schwartz, and E.-G. Kim, "Altered endocytosis in cellular
637 senescence.," *Ageing Res Rev*, vol. 68, p. 101332, Jul. 2021, doi:
638 10.1016/j.arr.2021.101332.
- 639 [42] O. Moujaber *et al.*, "Cellular senescence is associated with reorganization of the
640 microtubule cytoskeleton," *Cellular and Molecular Life Sciences*, vol. 76, no. 6, pp. 1169–
641 1183, Mar. 2019, doi: 10.1007/s00018-018-2999-1.
- 642 [43] D. Muñoz-Espín *et al.*, "Programmed Cell Senescence during Mammalian Embryonic
643 Development," *Cell*, vol. 155, no. 5, pp. 1104–1118, Nov. 2013, doi:
644 10.1016/J.CELL.2013.10.019.
- 645 [44] C. Abbadie, O. Pluquet, and A. Pourtier, "Epithelial cell senescence: an adaptive
646 response to pre-carcinogenic stresses?," *Cellular and Molecular Life Sciences*, vol. 74,
647 no. 24, pp. 4471–4509, Dec. 2017, doi: 10.1007/s00018-017-2587-9.
- 648 [45] C. A. Valenzuela, R. Quintanilla, R. Moore-Carrasco, and N. E. Brown, "The Potential
649 Role of Senescence As a Modulator of Platelets and Tumorigenesis.," *Front Oncol*, vol. 7,
650 p. 188, 2017, doi: 10.3389/fonc.2017.00188.
- 651 [46] V. J. D. Krouwer, L. H. P. Hekking, M. Langelaar-Makkinje, E. Regan-Klapisz, and J.
652 Post, "Endothelial cell senescence is associated with disrupted cell-cell junctions and
653 increased monolayer permeability," *Vasc Cell*, vol. 4, no. 1, p. 12, 2012, doi:
654 10.1186/2045-824X-4-12.
- 655 [47] M. S. Chen, R. T. Lee, and J. C. Garbern, "Senescence mechanisms and targets in the
656 heart.," *Cardiovasc Res*, vol. 118, no. 5, pp. 1173–1187, Mar. 2022, doi:
657 10.1093/cvr/cvab161.
- 658 [48] D. A. Gadd *et al.*, "Epigenetic scores for the circulating proteome as tools for disease
659 prediction," *Elife*, vol. 11, Jan. 2022, doi: 10.7554/eLife.71802.
- 660 [49] M. E. Levine, A. Higgins-Chen, K. Thrush, C. Minter, and P. Niimi, "Clock Work:
661 Deconstructing the Epigenetic Clock Signals in Aging, Disease, and Reprogramming",
662 doi: 10.1101/2022.02.13.480245.
- 663 [50] D. McHugh and J. Gil, "Senescence and aging: Causes, consequences, and therapeutic
664 avenues," *Journal of Cell Biology*, vol. 217, no. 1, pp. 65–77, Jan. 2018, doi:
665 10.1083/jcb.201708092.
- 666 [51] S. Kabacik *et al.*, "The relationship between epigenetic age and the hallmarks of aging in
667 human cells," *Nature Aging 2022 2:6*, vol. 2, no. 6, pp. 484–493, May 2022, doi:
668 10.1038/s43587-022-00220-0.

- 669 [52] R. Waziry *et al.*, “Effect of long-term caloric restriction on DNA methylation measures of
670 biological aging in healthy adults from the CALERIE trial,” *Nature Aging* 2023 3:3, vol. 3,
671 no. 3, pp. 248–257, Feb. 2023, doi: 10.1038/s43587-022-00357-y.
- 672 [53] A. Tomusiak *et al.*, “Development of a novel epigenetic clock resistant to changes in
673 immune cell composition,” *bioRxiv*, p. 2023.03.01.530561, Mar. 2023, doi:
674 10.1101/2023.03.01.530561.
- 675 [54] E. L. S. Conole *et al.*, “DNA Methylation and Protein Markers of Chronic Inflammation and
676 Their Associations With Brain and Cognitive Aging,” *Neurology*, vol. 97, no. 23, pp.
677 e2340–e2352, Dec. 2021, doi: 10.1212/WNL.00000000000012997.
- 678 [55] Q. Luo *et al.*, “A meta-analysis of immune cell fractions at high resolution reveals novel
679 associations with common 2 phenotypes and health outcomes”, doi:
680 10.1101/2023.03.20.533349.
- 681 [56] B. C. Christensen and K. T. Kelsey, “A new timepiece: An epigenetic mitotic clock,”
682 *Genome Biol*, vol. 17, no. 1, pp. 1–3, Oct. 2016, doi: 10.1186/S13059-016-1085-
683 Y/METRICS.
684

A**B****C**

A**B**

A**B**

3-month blood sample

6-month blood sample

Baseline blood sample

6-month blood sample

1 year

Nov
2020

Feb
2021


May
2021

Jun
2022


Nov
2022

50mg Dasatinib + 500mg Quercetin

**50mg Dasatinib + 500mg Quercetin +
500mg Fisetin**



N = 19



N = 10

N = 9

N = 19